Cover Image
市場調查報告書

乳癌治療藥的全球市場的競爭分析

A Competitive Analysis of the Global Breast Cancer Therapeutics Market

出版商 Frost & Sullivan 商品編碼 325787
出版日期 內容資訊 英文 68 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乳癌治療藥的全球市場的競爭分析 A Competitive Analysis of the Global Breast Cancer Therapeutics Market
出版日期: 2015年03月09日 內容資訊: 英文 68 Pages
簡介

乳癌治療藥的市場上,以新等級的標靶治療藥為首,進行各種新產品臨床實驗、上市,那成為推升整體市場成長率的要素。

本報告提供全球的乳癌治療藥市場上競爭狀態相關分析、各類藥物的技術、市場趨勢和補充資訊 (臨床實驗的時間軸、成果、已上市/上市預定的產品時間表、流行病學的資訊等)、主要的已上市產品/開發中產品的一覽、目前臨床實驗的進展的資訊彙整,為您概述為以下內容。

第1章 摘要整理

  • 摘要整理
  • 乳癌治療的醫生的指南:Her 2陽性的情況
  • 乳癌治療的醫生的指南:ER/PR陽性的情況
  • 乳癌治療的醫生的指南:三重陰性的情況
  • 主要趨勢
  • 市場機會
  • 值得注意的企業

第2章 摘要整理

  • 調查手法及分析範圍

第3章 市場概要

  • 市場概要:簡介
  • 市場概要:乳癌的發病率
  • 市場規模
  • 市場區隔

第4章 競爭情形:乳癌的已上市產品及開發平台候補藥

  • 競爭情形:概要
  • 競爭情形:乳癌的已上市/開發中產品
  • 已上市產品:荷爾蒙療法
  • 已上市產品:標靶治療
  • 已上市產品:化療
  • 開發中產品:化療
  • 開發中產品:其他治療方法
  • 產品上市的時間軸
  • 專利失效

第5章 重要的第三階段臨床實驗

  • 乳癌治療藥:現在進展中/近幾年完成的臨床實驗
  • 值得注意的主要產品:摘要

第6章 產品開發動態即時看板系統 (已上市產品及第三階段候補藥)

  • 產品開發動態即時看板系統:Herceptin (Trastuzumab)
  • 產品開發動態即時看板系統:Afinitor (Everolimus)
  • 產品開發動態即時看板系統:Arimidex (Anastrozole)
  • 產品開發動態即時看板系統:Perjeta (Pertuzumab)
  • 產品開發動態即時看板系統:Tykerb (Lapatinib)
  • 產品開發動態即時看板系統:Taxol (Paclitaxel)
  • 產品開發動態即時看板系統:Xeloda (Capecitabine)
  • 產品開發動態即時看板系統:Kadcyla (Ado-trastuzumab emtansine)
  • 產品開發動態即時看板系統-PD-0332991 (Palbociclib)
  • 產品開發動態即時看板系統- NeuVax(Nelipepimut-S)

第7章 結論

第8章 附錄

  • 決策依據的資料庫

第9章 關於FROST & SULLIVAN

目錄
Product Code: MADE-01-00-00-00

A New Class of Targeted Therapeutics Offers Novel Treatment Modalities to Treat Difficult Breast Cancers

The study assesses marketed and investigational products and combination regimens for the global breast cancer therapeutics market. Segmentation by drug class is provided, along with supporting information, such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. Marketed and pipeline products are broadly segmented into hormonal therapy, targeted therapy, chemotherapy, and other therapies of current global interest. A large number of products in clinical development and the rising demand for breast cancer therapeutics are the key market drivers.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • 1. Executive Summary
  • 2. Executive Summary (continued)
  • 3. Physician Guidelines to Breast Cancer Therapy-Her 2 Positive
  • 4. Physician Guidelines to Breast Cancer Therapy-ER or PR Positive
  • 5. Physician Guidelines to Breast Cancer Therapy-Triple-negative Breast Cancer
  • 6. Key Trends
  • 7. Market Opportunities
  • 8. Companies to Watch

2. EXECUTIVE SUMMARY

Executive Summary

  • 1. Methodology and Scope

3. MARKET OVERVIEW

Market Overview

  • 1. Market Overview-Introduction
  • 2. Market Overview-Introduction (continued)
  • 3. Market Overview-Incidence Rate of Breast Cancer
  • 4. Market Size
  • 5. Market Segmentation

4. COMPETITIVE LANDSCAPE-BREAST CANCER MARKETED PRODUCTS AND PIPELINE CANDIDATES

Competitive Landscape-Breast Cancer Marketed Products and Pipeline Candidates

  • 1. Competitive Landscape Overview
  • 2. Competitive Landscape-Breast Cancer Marketed and Pipeline Products
  • 3. Marketed Products-Hormone Therapy
  • 4. Marketed Products-Hormone Therapy (continued)
  • 5. Pipeline Products-Hormone Therapy (continued)
  • 6. Marketed Products-Targeted Therapy
  • 7. Pipeline Products-Targeted Therapy (continued)
  • 8. Pipeline Products-Targeted Therapy (continued)
  • 9. Marketed Products-Chemotherapy
  • 10. Marketed Products-Chemotherapy (continued)
  • 11. Pipeline Products-Chemotherapy
  • 12. Pipeline Products-Other Therapies
  • 13. Product Launch Timeline
  • 14. Patent Expirations

5. PIVOTAL PHASE 3 TRIALS

Pivotal Phase 3 Trials

  • 1. Breast Cancer Therapeutics-Major Ongoing/Recently Completed Clinical Trials
  • 2. Breast Cancer Therapeutics-Major Ongoing/Recently Completed Clinical Trials (continued)
  • 3. Breast Cancer Therapeutics-Major Ongoing/Recently Completed Clinical Trials (continued)
  • 4. Summary of Key Products to Watch

6. PRODUCT DASHBOARD (MARKETED PRODUCTS AND PHASE 3 CANDIDATES)

Product Dashboard (Marketed Products and Phase 3 Candidates)

  • 1. Product Dashboard-Herceptin (Trastuzumab)
  • 2. Product Dashboard-Afinitor (Everolimus)
  • 3. Product Dashboard-Arimidex (Anastrozole)
  • 4. Product Dashboard-Perjeta (Pertuzumab)
  • 5. Product Dashboard-Tykerb (Lapatinib)
  • 6. Product Dashboard-Taxol (Paclitaxel)
  • 7. Product Dashboard-Xeloda (Capecitabine)
  • 8. Product Dashboard-Kadcyla (Ado-trastuzumab emtansine)
  • 9. Product Dashboard-PD-0332991(Palbociclib)
  • 10. Product Dashboard-NeuVax (Nelipepimut-S)

7. CONCLUSIONS

Conclusions

  • 1. Conclusions
  • 2. Legal Disclaimer

8. APPENDIX

Appendix

  • 1. Decision Support Database
  • 2. Decision Support Database (continued)
  • 3. Decision Support Database (continued)

9. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

  • 1. The Frost & Sullivan Story
  • 2. Value Proposition
  • 3. Global Perspective
  • 4. Industry Convergence
  • 5. 360° Research Perspective
  • 6. Implementation Excellence
  • 7. Our Blue Ocean Strategy
Back to Top